Claims for Patent: 7,892,749

Summary for Patent: 7,892,749

Title:	Methods for differentiating and monitoring parathyroid and bone status related diseases
Abstract:	The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states In specific embodiments, the present invention relates to isolated antibodies, including polyclonal antibodies, that specifically bind to a three-dimensional epitope of a parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of the isolated antibodies, and the isolated antibodies do not specifically bind to a non-(1-84) PTH fragment, e.g., a PTH.sub.7-84 fragment. Therapeutic compositions and kits comprising the isolated antibodies are also provided.
Inventor(s):	Cantor; Thomas L. (El Cajon, CA), Gao; Ping (San Diego, CA)
Assignee:	Scantibodies Laboratory, Inc. (Santee, CA)
Application Number:	10/760,091
Patent Claims:	1. An isolated antibody that specifically binds to a three-dimensional epitope of a parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated antibody, and said isolated antibody does not specifically bind to a non-(1-84) PTH fragment. 2. The isolated antibody of claim 1, wherein the parathyroid hormone is human parathyroid hormone. 3. A therapeutic composition comprising an isolated antibody that specifically binds to a three-dimensional epitope of a parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated antibody, and said isolated antibody does not specifically bind to a non-(1-84) PTH fragment, and a pharmaceutically-acceptable carrier. 4. The antibody of claim 1, wherein the antibody reduces adenylate cyclase activity by binding to the three-dimensional epitope of the parathyroid hormone. 5. The antibody of claim 1, wherein the antibody is a polyclonal antibody. 6. The antibody of claim 1, wherein the antibody is a monoclonal antibody. 7. The antibody of claim 1, wherein the antibody is an antibody fragment. 8. The antibody of claim 1, which is coupled to a detectable marker. 9. An isolated polyclonal antibody that specifically binds to a three-dimensional epitope of human parathyroid hormone (PTH) produced by a process comprising the following steps: a) immunizing an animal with human whole PTH as a primary immunization; b) immunizing said animal with human whole PTH subsequent to said primary immunization; c) recovering a polyclonal antibody from said animal, and d) isolating said polyclonal antibody by binding said polyclonal antibody to at least four amino acids in the common sequence of human and rat PTH (1-8) sequence, whereby said polyclonal antibody specifically binds to said three-dimensional epitope in human PTH.sub.1-8 as part of whole human PTH, at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated polyclonal antibody, and said isolated polyclonal antibody does not specifically bind to a non-(1-84) PTH fragment. 10. A kit comprising an isolated antibody that specifically binds to a three-dimensional epitope of parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated antibody and said isolated antibody does not specifically bind to a non-(1-84) PTH fragment. 11. The kit of claim 10, wherein the antibody is coupled with a detectable label. 12. The kit of claim 10, further comprising a tool for obtaining a biological sample containing parathyroid hormone from a patient. 13. The kit of claim 11, wherein the detectable label is selected from the group consisting of a chemiluminescent marker, a fluorescent marker, a radioactive marker, and an enzymatic marker. 14. The isolated antibody of claim 1, wherein the non-(1-84) PTH fragment is a PTH.sub.7-84 fragment. 15. The therapeutic composition of claim 3, wherein the non-(1-84) PTH fragment is a PTH.sub.7-84 fragment. 16. The kit of claim 10, wherein the non-(1-84) PTH fragment is a PTH.sub.7-84 fragment. 17. The isolated antibody of claim 1, wherein PTH.sub.1-6 is part of the reactive portion of the isolated antibody. 18. The isolated antibody of claim 1, wherein PTH.sub.1-7 is part of the reactive portion of the isolated antibody. 19. The isolated antibody of claim 1, wherein PTH.sub.1-8 is part of the reactive portion of the isolated antibody. 20. The therapeutic composition of claim 3, wherein PTH.sub.1-6 is part of the reactive portion of the isolated antibody. 21. The therapeutic composition of claim 3, wherein PTH.sub.1-7 is part of the reactive portion of the isolated antibody. 22. The therapeutic composition of claim 3, wherein PTH.sub.1-8 is part of the reactive portion of the isolated antibody. 23. The isolated polyclonal antibody of claim 9, wherein PTH.sub.1-6 is part of the reactive portion of the isolated antibody. 24. The isolated polyclonal antibody of claim 9, wherein PTH.sub.1-7 is part of the reactive portion of the isolated antibody. 25. The isolated polyclonal antibody of claim 9, wherein PTH.sub.1-8 is part of the reactive portion of the isolated antibody. 26. The kit of claim 10, wherein PTH.sub.1-6 is part of the reactive portion of the isolated antibody. 27. The kit of claim 10, wherein PTH.sub.1-7 is part of the reactive portion of the isolated antibody. 28. The kit of claim 10, wherein PTH.sub.1-8 is part of the reactive portion of the isolated antibody. 29. An isolated antibody that specifically binds to a three-dimensional epitope of a parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated antibody, and said isolated antibody does not specifically bind to a PTH.sub.7-84 fragment. 30. A therapeutic composition comprising an isolated antibody that specifically binds to a three-dimensional epitope of a parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated antibody, and said isolated antibody does not specifically bind to a PTH.sub.7-84 fragment, and a pharmaceutically-acceptable carrier. 31. An isolated polyclonal antibody that specifically binds to a three-dimensional epitope of human parathyroid hormone (PTH) produced by a process comprising the following steps: a) immunizing an animal with human whole PTH as a primary immunization; b) immunizing said animal with human whole PTH subsequent to said primary immunization; c) recovering a polyclonal antibody from said animal, and d) isolating said polyclonal antibody by binding said polyclonal antibody to at least four amino acids in the common sequence of human and rat PTH (1-8) sequence, whereby said polyclonal antibody specifically binds to said three-dimensional epitope in human PTH.sub.1-8 as part of whole human PTH, at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated polyclonal antibody, and said isolated polyclonal antibody does not specifically bind to a PTH.sub.7-84 fragment. 32. A kit comprising an isolated antibody that specifically binds to a three-dimensional epitope of parathyroid hormone (PTH) in PTH.sub.1-8 as part of whole PTH, wherein at least four amino acids in PTH.sub.1-8 are part of the reactive portion of said isolated antibody and said isolated antibody does not specifically bind to a PTH.sub.7-84 fragment.

Details for Patent 7,892,749

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-01-14